Summit Therapeutics PLC (SMMT) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $15.80
• Market Cap: $11.67B
• EPS: $-1.25
• 52-Week High: $36.91
• 52-Week Low: $13.83

Market Sentiment

Summit Therapeutics PLC currently has a Neutral sentiment score of -0.01.

About Summit Therapeutics PLC

Summit Therapeutics PLC is a biopharmaceutical company headquartered in Cambridge, Massachusetts, specializing in the discovery and development of innovative treatments for infectious diseases. Leveraging its proprietary drug development platforms, Summit focuses on addressing significant unmet medical needs across its strategic operations in the United States, Latin America, and Europe. The company is committed to advancing patient care by delivering transformative therapies that improve the...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Summit Therapeutics PLC and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does SMMT pay dividends?

Summit Therapeutics PLC (SMMT) does not currently pay a regular dividend.

What is SMMT's market cap?

Summit Therapeutics PLC (SMMT) has a market capitalization of $11.67B with a current stock price of $15.80.